Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now?
Personalization is all the rage these days. Whether we're talking about the business of entertainment, food, or clothing, consumers have more options today than anyone imagined possible a couple of decades ago.
(NASDAQ: MRNA) and its big pharma collaboration partner, Merck (NYSE: MRK), recently posted compelling clinical-trial results that suggest cancer treatments are about to become a lot more personalized too. On Monday, June 5, the partners showed off compelling results for a personalized cancer vaccine that Moderna calls mRNA-4157 and Merck calls V940.
There are a whole lot of ins and outs when it comes to interpreting cancer-trial data. Let's look at the most important details to see if Moderna's a smart stock to buy now.
Source Fool.com
Moderna Inc. Aktie
Die Aktie ist durchaus ein Favorit unsere Community mit 21 Buy-Einschätzungen und 2 Sell-Einschätzungen.
Das von der Community festgelegte Kursziel von 129 € für Moderna Inc. bedeutet eine mögliche Steigerung um über 50% im Vergleich zu 78.79 €.
